Vaccine · Immune activation · developed by Valneva Austria GmbH
IC47 is an agent given by intramuscular injection at 30 or 150 mcg, three times at Day 0, Day 42 and Day 84. It is studied in pneumococcal infections.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00873431 | Phase 1 | Pneumococcal Infections | Completed | VALN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pneumococcal Infections
Updated Oct 11, 2026. Something wrong or missing? Report it on the VALN page.
See VALN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VALN catalysts and pipeline →